A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary) ; Mycophenolate mofetil; Tacrolimus
Indications Dry age-related macular degeneration
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Astellas Institute for Regenerative Medicine

18 Nov 2024 Planned End Date changed from 31 Jan 2026 to 30 Jun 2026.
18 Nov 2024 Planned primary completion date changed from 31 Jan 2026 to 30 Jun 2026.
22 Apr 2024 Planned End Date changed from 31 Dec 2025 to 31 Jan 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com